10 Geographic Atrophy Clinical Trials in Gainesville, FL (2026)

Q: How do I join a clinical trial in Gainesville?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Gainesville research site will contact you.

Recruiting Geographic Atrophy Studies in Gainesville

NCT06935357Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). This study will focus on participants who have protein in their urine ...

Gainesville, FL454 participantsBiogen

View Study Details

NCT07419334Recruiting

Study of ALK-001 on the Progression of Stargardt Disease

This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (ST...

Gainesville, FL230 participantsAlkeus Pharmaceuticals, Inc.

View Study Details

NCT06428409Recruiting

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the can...

Gainesville, FL220 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06596694Recruiting

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the bod...

Gainesville, FL180 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06632600Recruiting

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

This study is to investigate the ability of LXE408 to reduce or remove the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without ...

Gainesville, FL130 participantsNovartis Pharmaceuticals

View Study Details

NCT07215234Recruiting

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

This is a sequential Phase 1/2, two-part, multicenter study on safety, tolerability, and efficacy of one-time intravitreal SAR446597 for the treatment of participants with Geographic Atrophy (GA) seco...

Gainesville, FL104 participantsSanofi

View Study Details

NCT06435000Recruiting

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which wil...

Gainesville, FL75 participantsSplice Bio

View Study Details

NCT04485559Recruiting

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by t...

Gainesville, FL50 participantsUniversity of California, San Francisco

View Study Details

NCT06445322Recruiting

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials....

Gainesville, FL50 participantsAscidian Therapeutics, Inc

View Study Details

NCT06467344Recruiting

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for...

Gainesville, FL15 participantsAscidian Therapeutics, Inc

View Study Details

About Geographic Atrophy Clinical Trials in Gainesville

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 10 geographic atrophy clinical trials recruiting participants in Gainesville, FL. These studies are seeking a combined 1,508 participants. Research is being sponsored by Biogen, Alkeus Pharmaceuticals, Inc., Merck Sharp & Dohme LLC and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in Gainesville — FAQ

Are there geographic atrophy clinical trials in Gainesville?

Yes, there are 10 geographic atrophy clinical trials currently recruiting in Gainesville, FL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Gainesville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Gainesville research site will contact you about next steps.

Are clinical trials in Gainesville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Gainesville studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 10 active trials in Gainesville are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated July 13, 2026 from ClinicalTrials.gov